Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15166)	2/17/1998 10:33:00 AM
From: Andreas Helke	Read Replies (3) \| Respond to of 32384

I think the Zacks ratings are mechanically derived. And the most important ingredients to the formula are earnings surprises and altered estimates from analysts. Ligand qualifies with its smaller then expected losses and rising earnings estimates for 1999. I think the recent share price movement goes into the rating too. Andreas

To: Henry Niman who wrote (15166)	2/17/1998 9:10:00 PM
From: Abuckatatime	Read Replies (2) \| Respond to of 32384

Henry, I don't have anymore to contribute than what has already been provided on this ratings topic by you and others. I'm looking for a way to quickly access Zacks ratings (on the 1 to 5 scale) on any given company. I have three biotechs in my portfolio but only LGND carries the 1 rating. I agree that Ligand's improved ranking by Zacks proprietary system was largely the result of analyst's upward revisions of future earnings estimates.